|
Drugmakers Need Not Stress Over Post-FDASIA SQA Checks
BALTIMORE — While the new FDA user fee bill links supplier quality agreements (SQA) to drugmakers’ oversight responsibilities for the first time, it’s not likely such accords will be the focus of inspections any more than they are now, FDA officials say.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives